These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34799277)

  • 1. Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study.
    Donnez J; Donnez O; Brethous M; Bestel E; Garner E; Charpentier S; Humberstone A; Loumaye E
    Reprod Biomed Online; 2022 Jan; 44(1):200-203. PubMed ID: 34799277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of Administration.
    Donnez J; Donnez O; Tourniaire J; Brethous M; Bestel E; Garner E; Charpentier S; Humberstone A; Loumaye E
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis.
    Donnez O; Donnez J
    Fertil Steril; 2020 Sep; 114(3):640-645. PubMed ID: 32507315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
    Donnez J; Taylor HS; Taylor RN; Akin MD; Tatarchuk TF; Wilk K; Gotteland JP; Lecomte V; Bestel E
    Fertil Steril; 2020 Jul; 114(1):44-55. PubMed ID: 32505383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
    Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
    Hum Reprod; 2024 Jun; 39(6):1208-1221. PubMed ID: 38648863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis.
    Pohl O; Baron K; Riggs M; French J; Garcia R; Gotteland JP
    Br J Clin Pharmacol; 2022 May; 88(5):2359-2371. PubMed ID: 34904270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
    Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
    Dababou S; Garzon S; Laganà AS; Ferrero S; Evangelisti G; Noventa M; D'Alterio MN; Palomba S; Uccella S; Franchi M; Barra F
    Expert Opin Investig Drugs; 2021 Sep; 30(9):903-911. PubMed ID: 34278887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study.
    Guo Y; Duan H; Cheng J; Zhang Y
    BJOG; 2017 Aug; 124 Suppl 3():7-11. PubMed ID: 28856862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linzagolix: First Approval.
    Keam SJ
    Drugs; 2022 Aug; 82(12):1317-1325. PubMed ID: 35997940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials.
    Donnez J; Donnez O; Dolmans MM
    Fertil Steril; 2023 Nov; 120(5):1071-1073. PubMed ID: 37495010
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.
    Tezuka M; Tamai Y; Kuramochi Y; Kobayashi K; Fushimi N; Kiguchi S
    Clin Exp Pharmacol Physiol; 2022 Oct; 49(10):1082-1093. PubMed ID: 35690889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute dysmenorrhoea and pelvic pain syndrome of uterine origin with myometrial botulinum toxin injections under hysteroscopy: A pilot study.
    Bautrant E; Franké O; Amiel C; Bensousan T; Thiers-Bautrant D; Levêque C
    J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101972. PubMed ID: 33186771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis.
    Yan H; Shi J; Li X; Dai Y; Wu Y; Zhang J; Gu Z; Zhang C; Leng J
    Fertil Steril; 2022 Dec; 118(6):1102-1116. PubMed ID: 36283862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern.
    Pohl O; Marchand L; Bell D; Gotteland JP
    Reprod Sci; 2020 Apr; 27(4):988-995. PubMed ID: 32100275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic Uterine Artery Occlusion Combined with Uterine-sparing Pelvic Plexus Block and Partial Adenomyomectomy for Adenomyosis: A Video Case Report.
    Chen D; Ai G; Yang W; Liu J; Luo N; Guo J; Cheng Z
    J Minim Invasive Gynecol; 2021 Oct; 28(10):1681-1684. PubMed ID: 34051355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial.
    Sharma S; RoyChoudhury S; Bhattacharya MP; Hazra S; Majhi AK; Oswal KC; Chattopadhyay R
    Reprod Biomed Online; 2023 Jul; 47(1):84-93. PubMed ID: 37149412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and sonographic impact of oral contraception in patients with deep endometriosis and adenomyosis at 2 years of follow-up.
    Carrillo Torres P; Martínez-Zamora MÁ; Ros C; Rius M; Mensión E; Gracia M; Carmona F
    Sci Rep; 2023 Feb; 13(1):2066. PubMed ID: 36739298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study.
    Andersson JK; Khan Z; Weaver AL; Vaughan LE; Gemzell-Danielsson K; Stewart EA
    Acta Obstet Gynecol Scand; 2019 Oct; 98(10):1341-1350. PubMed ID: 31025313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists.
    Donnez J; Stratopoulou CA; Dolmans MM
    Int J Environ Res Public Health; 2021 Sep; 18(19):. PubMed ID: 34639243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.